Fig. 5.

Comparison of ratios of IL-4/IL-2, IL-5/IL-2, and IL-13/IL-2 in CMS-treated mice with and without NAI exposure. a The ratio of serous concentration of IL-4/IL-2. The one-way ANOVA test measured the significant differences between these groups {F[3,35] = 3.599, *P = 0.023; Bonferroni multiple comparisons test showed *P = 0.030 (CMS vs. Con); *P = 0.035 (CMS vs. CMS + NAI); **P = 0.003 (CMS vs. Con + NAI)}. b The ratio of serous concentration of IL-5/IL-2. The one-way ANOVA test measured the significant differences between these groups {F[3,35] = 3.981, *P = 0.015; Bonferroni multiple comparisons test showed *P = 0.018 (CMS vs. Con); P = **0.002 (Con + NAI vs. CMS)}. c The ratio of serous concentration of IL-13/IL-2. The one-way ANOVA test measured the significant differences between these groups {F[3,33] = 5.016, P = 0.006; Bonferroni multiple comparisons test showed *P = 0.024 (CMS vs. Con); **P = 0.001 (CMS + NAI vs. CMS); **P = 0.003 (CMS vs. Con + NAI)}. (*P < 0.05, ^**P < 0.01). 9 ≤ n ≤ 11/group